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Abstract
Background: We studied the distribution of causes of death in the CONTRAST cohort and compared the proportion of
cardiovascular deaths with other populations to answer the question whether cardiovascular mortality is still the principal
cause of death in end stage renal disease. In addition, we compared patients who died from the three most common death
causes. Finally, we aimed to study factors related to dialysis withdrawal.
Methods: We used data from CONTRAST, a randomized controlled trial in 714 chronic hemodialysis patients comparing the
effects of online hemodiafiltration versus low-flux hemodialysis. Causes of death were adjudicated. The distribution of
causes of death was compared to that of the Dutch dialysis registry and of the Dutch general population.
Results: In CONTRAST, 231 patients died on treatment. 32% died from cardiovascular disease, 22% due to infection and 23%
because of dialysis withdrawal. These proportions were similar to those in the Dutch dialysis registry and the proportional
cardiovascular mortality was similar to that of the Dutch general population. cardiovascular death was more common in
patients,60 years. Patients who withdrew were older, had more co-morbidity and a lower mental quality of life at baseline.
Patients who withdrew had much co-morbidity. 46% died within 5 days after the last dialysis session.
Conclusions: Although the absolute risk of death is much higher, the proportion of cardiovascular deaths in a prevalent end
stage renal disease population is similar to that of the general population. In older hemodialysis patients cardiovascular and
non-cardiovascular death risk are equally important. Particularly the registration of dialysis withdrawal deserves attention.
These findings may be partly limited to the Dutch population.
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Introduction
End-stage renal disease (ESRD) patients have a high cardio-
vascular (CV) mortality rate, which is substantially higher
compared to the general population, especially in young
subjects[1;2]. The United States (US) renal data system registry
reports 43% of deaths to be cardiovascular [3]. However,
mortality patterns differ considerably between ESRD patients
from the US, Europe and Asia [4]. Differences in patients who
start with dialysis, in selection of patients for transplantation and
peritoneal dialysis (PD) and in life expectancy between the areas
greatly affect mortality rates and cause specific mortality
distribution [4]. In the Dutch CONvective TRAnsport STudy
(CONTRAST) we found an incidence of CV mortality of 34/1000
person years in the patients treated with online hemodiafiltration
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(HDF) and 42/1000 person years in the patients treated with low-
flux hemodialysis (HD) [5]. Whereas the US HEMO study
reported 66 cardiac deaths per 1000 patients years [6] and the
ERA-EDTA reported a unstandardized CV mortality rate of 74.9
CV deaths per 1000 persons years for the period 1994–2004 in
European patients [7]. The latter study showed that patients
starting dialysis have a generally increased risk of death that is not
specifically caused by excess CV mortality [7].
The first objective of the present analysis was to compare the
distribution of death causes, in particular CV deaths, in the
CONTRAST cohort to the Dutch HD population and to the
Dutch general population. The second objective was to study
potential differences in risk factors between those who died from
cardiovascular disease (CVD), from infections or from dialysis
withdrawal. The third objective was to assess factors related to
dialysis withdrawal.
Methods
Study design and methods of CONTRAST have been
published before [5;8]. In short, CONTRAST was a randomized
controlled trial comparing effects of online HDF versus low-flux
HD on all-cause mortality and CV morbidity and mortality.
Patients with end-stage renal disease undergoing chronic inter-
mittent HD for at least two months and aged 18 years or above
were enrolled from June 2004 until January 2010 in twenty-nine
dialysis centers in The Netherlands (n = 26), Canada (n= 2), and
Norway (n= 1). Patients were eligible for inclusion if they were
treated two or three times per week with low-flux HD. Exclusion
criteria were: treatment with hemo(dia)filtration or high-flux HD
in the six months preceding randomization, a life expectancy less
than three months due to non-renal disease, participation in
another clinical intervention trial evaluating cardiovascular
outcomes and severe non-adherence regarding frequency and/or
duration of dialysis treatment.
The study was conducted in accordance with the Declaration of
Helsinki and approved by the medical ethics review boards of all
participating hospitals. Written informed consent was obtained
from all patients prior to enrolment.
Dialysis Procedures
Online HDF was performed in the post-dilution mode, with
synthetic high-flux dialyzers [5]. HD patients were treated with
synthetic low-flux dialyzers. All patients were treated with
ultrapure dialysis fluids, defined as less than 0.1 colony forming
units per mL and less than 0.03 endotoxin units per mL. Routine
patient care was performed according to national and interna-
tional Quality of Care Guidelines.
Data Collection
Standardized forms were used to collect demographical, clinical
and laboratory data. Type of vascular access, duration of dialysis
(dialysis vintage), medical history (presence of diabetes mellitus
(DM) and previous CVD), were recorded. CVD was defined as
previous stroke or transient ischemic attack, peripheral vascular
disease and/or coronary heart disease (CHD), including history of
angina pectoris, myocardial infarction or prior coronary revascu-
larization. Dialysis vintage was determined as the sum of time
patients were treated with HD or PD before inclusion. At each
three monthly visit, occurrence of clinical events was recorded.
Routine blood samples were drawn prior to dialysis. Patients with
a urinary production of less than 100 mL per day were considered
anuric.
Health Related Quality of Life 36 (SF-36)
Health related quality of life (HRQOL) was assessed with the
validated KDQOL-SF version 1.3 (http://www.rand.org/
[9;10], which contains the
SF-36 version 1 [11]. The eight domains of the SF-36 were
summarized into a physical functioning (Physical Component
Summary – PCS) and a mental functioning (Mental Component
Summary – MCS) score. These summaries are constructed so that
a score of 50 represents the mean of the general United States
population with a standard deviation of 10 [12]. A difference of 3
points in the summary score has been proposed to be clinically
relevant [11;12].
Laboratory Measurements
Routine measurements were done in the participating hospitals
using standard techniques. Serum albumin was measured in local
hospitals with the bromcresol green method or bromcresol purple
method and samples that were measured with the bromcresol
purple method were converted to bromcresol green concentrations
with the formula: bromcresol green= bromcresol purple+5.5 [13].
Inflammatory markers from 405 patients were measured centrally.
hsCRP (mg/L) was measured with a particle-enhanced immuno-
turbidimetric assay on a Roche-Hitachi analyzer (Roche Diag-
nostics GmbH, Mannheim, Germany), with a lower quantification
limit of 0.1 mg/L. IL-6 (pg/mL) was measured with an ELISA
(Sanquin, Amsterdam, The Netherlands), with a lower quantifi-
cation limit of 0.35 pg/mL.
Outcome
Cardiovascular deaths were defined as death from CV causes,
which included myocardial infarction, ischemic or haemorrhagic
stroke, sudden death (unexpected death within an hour of
symptom onset or unwitnessed, unexpected death without obvious
non-cardiac cause in patients known to be well within the past 24
hours), heart failure or other CV causes. Non-CV causes were
defined as death from infections, cancer, dialysis withdrawal,
unnatural deaths and other non CV causes, such as gastrointes-
tinal haemorrhage or respiratory insufficiency. If no documenta-
tion on the event was available, death was categorized as unknown
cause. An independent Endpoint Adjudication Committee re-
viewed source documentation (mostly discharge letters from
admissions to the hospital) for all deaths, to adjudicate the cause
of death using their clinical experience. Each case was reviewed by
three or, if necessary, four medical doctors and the cause of death
was defined when two doctors agreed. We made no priory
definition to adjudicate deaths as ‘dialysis withdrawal’. For patients
whose cause of death was adjudicated as dialysis withdrawal, we
retrieved source documentation and explored circumstances and
the interval between dialysis withdrawal and death.
The present analyses were restricted to patients who died either
during treatment with HD or HDF or who died within 28 days
after censoring due to transplantation, switch to PD, switch to
other hospital or stopping because of other reasons. The survivor
group consisted of patients who remained on HD or HDF during
the study up to the end of follow-up, or up to censoring.
Comparison CONTRAST with Other Registries
Renine. Renine is the nation-wide Dutch registry for HD
patients with a 100% coverage [14]. We used data from the year
2008, because patients in CONTRAST were included between
2004–2010. Cause of death was coded using the ERA-EDTA
codes [15]. Code 11 denotes acute myocardial infarction, code 22
strokes and codes 12 and 15 sudden death. Codes 14, 16 and 18
Causes of Death in ESRD
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health/s    urveys _           – tools/kdqol.html) 
denote heart failure and codes 13, 26 and 29 other CV causes. We
used code 30–39 for infections, code 66 and 67 for cancer and
code 51, 53 and 61 for withdrawal from HD. Code 17, 21, 23–25,
27–28, 41–44, 46, 62–64, 69–73, 90 and 102 were categorized as
other non CV death. Code 52 and 80–82 were categorized as
unnatural event and code 99 and 0 and ‘cause of death not yet
registered’ were classified as unknown cause of death.
General population of the Netherlands. Causes of death
of the general population were obtained at the central office of
statistics of the Netherlands [16]. Eurostat ICD codes were used to
classify causes of death in 2008 [17]. To determine the number of
deaths from a CVD cause we used the number from ‘total deaths
from CV diseases’ (ICD-10 I00-I99) minus the numbers of deaths
caused by pulmonary embolism or other diseases of pulmonary
origin (I26–28), or by infectious causes of heart disease, such as
endocarditis (I33, 38–41), or by diseases from veins, arterioles,
capillaries and lymph vessels I78–89 and by hypotension (I95).
Data Analysis
Comparison CONTRAST with the Dutch general
population. We multiplied the 5 year age and sex specific
mortality rates from the Dutch population with the age and sex
specific number of person years in CONTRAST to obtain an
estimate of the number of CV deaths and total deaths expected,
had the Dutch mortality rate be applicable for CONTRAST.
Next we summed the age and sex specific expected numbers of
death to obtain an overall number of CV and total deaths. Next,
the proportion of expected CV death/total expected death was
estimated to come up with a proportion CV death in
CONTRAST, had the general population mortality rates been
applicable for the CONTRAST population.
Baseline characteristics of patients in CONTRAST by
cause of death. To compare the baseline characteristics of the
patients by cause of death, we ran multivariable regression models,
adjusted for age and sex. To compare medication use between the
different causes of death, we additionally adjusted for history of
CVD. We performed Chi square test to explore differences in
causes of death by the age groups younger than 60, 60–75 and
older than 75 years. Two sided P-values below 0.05 were
considered statistically significant. These analyses were conducted
with SPSS software (version 18.0; SPSS Inc. Headquarters,
Chicago, Illinois, US).
Results
Baseline characteristics are given in Table 1.
Causes of Death in CONTRAST
Two hundred thirty one patients died. Seventy-four patients
(32%) died from CV causes and 142 patients (62%) died from non
CV causes. Infections (22% of all deaths) and dialysis withdrawal
(23% of all deaths) were the main non CV causes of death. In 7%
of cases the cause of death was unknown (Table 2).
Death Causes in Renine
Renine comprised 4921 patients at the first of January 2008,
with a mean age of 64.4 years and 59.7% men. 27% of deaths was
of CV origin. Sudden death was the cause of death in 9% of cases.
Sixteen percent of patients died from an infection and 19%
withdrew from dialysis treatment. In 25% the death cause was
unknown (Table 2).
Table 1. Baseline characteristics of the CONTRAST
participants.
Variable
CONTRAST
participants = 714
Age (years) 64.1613.7
Male sex - no. (%) 445 (62)
Region
- Netherlands – no. (%) 597 (84)
- Canada- no. (%) 102 (14)
- Norway – no. (%) 15 (14)
History of cardiovascular disease – no. (%) 313 (44)
Diabetes mellitus – no. (%) 170 (24)
Dialysis vintage (years) 2 (1–4)
Systolic blood pressure (mmHg), 147621
Diastolic blood pressure (mmHg), 75612
Body weight (kg) 72.4614.4
BMI after dialysis (kg/m2) 25.464.8
Residual kidney function – no. (%)* 376 (53)
eGFR (ml/min/1.73 m2) 3.2 (1.3–5.5)
Treatment frequency
3x/week – no. (%) 668 (94)
22x/week – no. (%) 44 (6)
Duration of a dialysis session – min 226623
Bloodflow (mL/min) 308639
Dialysis access – no. (%)
-Fistula 567 (80)
-Graft 100 (14)
-Central catheter 47 (6)
spKt/Vurea 1.4060.22
Hemoglobin (mmol/L) 7.360.78
Phosphorus – mmol/L 1.6460.49
Beta-2-microglobulin – mg/L 31.5614
Albumin (g/L)‘ 40.463.8
Creatinine (mmol/L), pre-dialysis 8616255
C-reactive protein mg/L (n = 405) 3.9 (1.4–10.4)
Interleukin-6 pg/mL (n = 403) 2.1 (1.2–3.8)
Quality of life
Physical Composite score 39611
Mental Composite score 50612
Prescribed medication – no. of patients(%)
Beta blocker 53
Alfa blocker 10
RAAS inhibitor 49
Statin 51
Platelet aggregation inhibitor 31
Values are means 6SD, median (interquartile range) or number (percentage).
,pre-dialysis.
*residual kidney function if diuresis .100 ml/24 h.
‘albumin concentrations measured with the bromcresolpurple method have
been converted to the bromcresolgreen method.
eGFR= estimated glomerular filtration rate; RAAS = renine angiontensin
aldosterone system.
To convert hemoglobin in mmol/L to g/dL divide by 0.62; phosphorus in mmol/L
to mg/dL, divide by 0.323; albumin in g/L to g/dL, divide by 10; creatinine in
mmol/L to mg/dL divide by 88.4.
doi:10.1371/journal.pone.0061155.t001
Causes of Death in ESRD
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e61155
The Percentage CV Death in CONTRAST when Dutch
General Population Rates Apply
The expected number of CV- deaths in CONTRAST when the
general population mortality rates were applied was 10.2; 7.7 in
men and 2.5 in women. The expected number of all cause death
was 35.5; 26.4 in men and 9.2 in women. The contribution of CV-
death to all-cause death would therefore be 27.8% (95% CI 13.1–
42.4%) based on general population mortality rates. In CON-
TRAST the proportion of CV-death was 32.0% (95% CI 26.0–
38.0%). (Table 3).
Baseline Characteristics of Patients in CONTRAST by
Cause of Death
Patients that died from CVD were younger (age at time of
death: 71.1 (IQR 65.9–78.9)) than patients dying from infections
(76.9 (70.3–81.4)) or after dialysis withdrawal (76.4 (69.2–80.6)
(Table 4). The proportion of CV death was larger in patients
younger than 60 years old than in patients aged 60–75 and older
than 75 years (Figure 1, P=0.02).
After adjustment for age and sex, patients dying from CVD had
a significantly higher prevalence of previous CVD and CHD
compared to patients dying from infections. Patients who died
from infection were more likely to have a graft as vascular access
than the patients who died from CVD or dialysis withdrawal.
They also had higher b2-microglobulin (b2m) levels at baseline.
Patients, who died after dialysis withdrawal, had the most co-
morbidity at baseline, namely more often a history of CVD, more
specifically previous CHD, cerebral vascular disease or peripheral
arterial disease. Also their prevalence of DM was higher. Their
mental quality of life at baseline, as reflected by the MCS, was
significantly worse than in survivors.
Exploration of those who died after Dialysis Withdrawal
Dying of patients after dialysis withdrawal (n = 54) was often
preceded by a (long) hospital stay. Three factors associated with
dialysis withdrawal were identified: acute complications, chronic
complications and low quality of life. In 18 patients dialysis was
stopped in a period in which an acute complication occurred: in
11 patients an infection was present or suspected, 7 patients had
peripheral vascular disease with a need for intervention and 7
patients had a gastrointestinal or shunt bleeding. Some patients
suffered from combined complications. In 25 patients dialysis was
stopped because of chronic complications: in 4 patients cancer was
suspected, in others cachexia, dementia, poor general condition,
pain, dyspnea, hypotension (in 3 patients due to aorta-valve
stenosis) and infections were associated with dialysis withdrawal.
Eleven patients withdrew from dialysis because of a low quality of
life. The median number of days between withdrawal and death
was 6 (IQR 2–9)(these data were available for 39 patients). 46%
died within 5 days after the last dialysis session.
Discussion
In this study we found that in ESRD patients approximately one
third of deaths was of CV origin. The proportion of CV death was
comparable with that in Dutch registry of dialysis patients
(Renine), and in the general population. The contribution of CV
death was larger in younger patients. The other main causes of
death were withdrawal from dialysis (23%) and infection (22%).
Patients, who withdrew from dialysis, had considerable co-
morbidity.
Compared to other studies in dialysis patients the proportion
CVD deaths in CONTRAST was low [3;18;19]. Our study seems
representative for the Dutch situation, given the comparability
with death causes registered in Renine. The European ERA-
EDTA registry reported a CV death proportion of 39% [7]. In the
Table 2. Causes of death in CONTRAST and Renine.
Cause of Death CONTRAST deaths Renine deaths of 2008¥
Cardiovascular n % 95% CI of % n % 95% CI of %
Acute Myocardial Infarction 8 3.5 (1.1–5.8) 73 6.5 (5.0–7.9)
Cerebrovascular Accident‘ 6 2.6 (0.5–4.6) 41 3.6 (2.5–4.7)
Sudden death 37 16.0 (11.3–20.7) 105 9.3 (7.6–11.0)
Heart failure 11 4.8 (2.0–7.5) 62 5.5 (4.2–6.8)
Other cardiovascular 12 5.2 (2.3–8.1) 27 2.4 (1.5–3.3)
Total cardiovascular 74 32.0 (26.0–38.0) 308 27.2 (24.6–29.8)
Non cardiovascular
Infection 51 22.1 (16.7–27.4) 180 15.9 (13.8–18.0)
Cancer 14 6.1 (3.0–9.1) 81 7.2 (5.7–8.7)
Unnatural death 3 1.3 (0–2.8) 8 0.7 (0.2–1.2)
Dialysis withdrawal 54 23.4 (17.9–28.8) 217 19.2 (16.9–21.5)
Other non cardiovascular 20 8.7 (5.0–12.3) 59 5.2 (3.9–6.5)
Total non cardiovascular 142 61.5 (55.2–67.7) 545 51.0 (45.2–51.1)
Unknown 15 6.5 (3.3–9.7) 247 21.8 (19.4–24.2)
Miscellaneous n.a. n.a. n.a. 32 2.8 (1.9–3.8)
Total number of deaths 231 100 1132 100
¥Renine population January 1st 2008: 4921 hemodialysis patients, mean age 64.4 years, 59.7% male.
‘Cerebrovascular accident ischemic or hemorrhagic.
n.a. = not applicable.
doi:10.1371/journal.pone.0061155.t002
Causes of Death in ESRD
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Table 4. Baseline characteristics of patients who died during follow-up, from cardiovascular death, infection or dialysis withdrawal
and of patients who survived (on treatment analysis).
Characteristics
Cardiovascular
death (n =74)
Fatal
infection (n =51)
Dialysis
withdrawal (n =54)
Survivors
(n=483)
Mean/
Median
SD
or IQR
Mean/
Median
SD
or IQR
Mean/
Median
SD
or IQR
Mean/
Median
SD
or IQR
Demographic
Age at randomisation (yrs) 69.4‘ 10 72.9‘ 10 72.9‘ 8 60.4 14
Age at time of death 71.3 10 75.1 10 74.7 8 n.a.
Sex (% man) 67.6 68.6 66.7 59.0
Systolic BP (mmHg) 150 21 146 25 146 21 147 21
Diastolic BP (mmHg) 74 11 74 13 71 11 77 12
History of CVD (%) 66.2"‘ 47.1# 64.8"‘ 36.0
AMI 23.3" 10 22.2 11.4
CHD 47.3"‘ 32 48.2‘ 23.2
Stroke/TIA 19.4 16 27.8‘ 12.5
PAD 21.6 23.5 29.6‘ 11.8
DM (%) 27.4 22# 41.5"‘ 23.1
BMI (kg/m2) 24.9 4 25.8 6 25.7 6 25.5 5
Smoking (%yes) 25.4 16 13.5 19.5
RKF (%yes) 48.7 41.2‘ 46.3‘ 54.5
Dialysis related
Dialysis vintage at randomization (yrs) 1.6 (1.1–3.7) 2.8 (1.0–5.7) 2.9 (1–4.5) 1.9 (1.0–3.9)
Total dialysis vintage at death* (yrs) 3.9 (2.3–5.8) 4.1 (2.4–6.1) 4.7 (3.2–6.1) 4.6 (3.0–6.3)
Vascular access (%)
AV-fistula 81.1 68.6 75.9 81.0
CVC 4.1 3.9 11.1 6.4
Graft 13.5" 27.5#‘ 13.0 12.0
Laboratory
Hemoglobin (mmol/L) 7.3 0.7 7.4 0.8 7.3 0.8 7.3 0.8
Albumin (g/L) 39‘ 4 40 4 39‘ 4 41 4
Creatinin (mmol/L) 792 244 794 220 742‘ 231 902 257
Calcium (mmol/L) 2.3 0.2 2.3 0.1 2.3 0.2 2.3 0.2
Phosphorus (mmol/L) 1.6 0.4 1.6 0.5 1.6 0.5 1.7 0.5
Parathyroid hormone (pmol/L) 22.1 (3.9–33) 16.3 (9–32) 17.5 (10–31) 21.9 (11–38)
B2-microglobulin (mg/L) 30.6" 14 35.9‘ 15 30.7 13 31.3 14
Hs-CRP (mg/L) 8.9‘n= (2.3–17.1) 5.7‘n= (3.2–14.2) 9.3‘ (4.2–25.2) 3.0 (1.0–7.3)
IL-6 (pg/mL) 2.5‘n= (1.9–4.0) 3.7‘ (2.5–4.5) 3.6‘ (1.5–8.7) 1.7 (1.1–2.9)
Quality of Life
SF-36 PCS 37‘ 11 37‘ 11 33‘ 8 42 10
SF-35 MCS 52# 11 51‘ 11 50‘ 16 53 11
Medication (% yes)
Calcium antagonist 39# 36# 15 32
Beta blocker 62# 52 41‘ 52
RAAS blocker 47.3 34‘ 35‘ 53.3
Alfa blocker 9 6 2 11
Statin 58# 42‘ 39‘ 52
Platelet aggregation inhibitor 42 34 37 29
n.a. = not applicable; CVD= cardiovascular disease; AMI = acute myocardial infarction; CHD= coronary heart disease; TIA = transient ischemic accident; PAD=peripheral
artery disease; DM=diabetes mellitus; BMI = body mass index; RKF = residual kidney function; AV = arterio-venous; CVC = central venous catheter; CRP = C- reactive
protein;
IL-6 = interleukin-6; PCS = physical composite score; MCS=mental composite score; RAAS = renin angiotensin aldosterone system.
‘significantly different as compared to survivors, after adjustment for age and sex.
#significantly different as compared to deaths due to dialysis withdrawal, after adjustment for age and sex.
"significantly different as compared to deaths due to infection, after adjustment for age and sex.
*total vintage at time of end of study or date of drop-out for survivors.
doi:10.1371/journal.pone.0061155.t004
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4D study and in the United States Renal Data System (USRDS)
CV deaths accounted for approximately 50% of all deaths [3;18].
In DOPPS III, CV death ranged from 29% in patients older than
75 years in Australia and New Zealand to 41% in patients aged
45–75 years in Europe and 56% in patients younger than 45 years
in North America [19]. The discrepancies between our study and
US studies are larger than between our study and other European
studies. The differences between the US and the Netherlands may
be a result of differences in patient selection for HD and
transplantation, as well as differences in clinical practice.
Importantly, the proportion of CV deaths was not different
from what would have been expected using the general population
estimates. This is in agreement with the EDTA registry data,
showing that CV and non CV death are similarly distributed
among incident dialysis patients and the general population [7]. As
in CONTRAST, they showed that in patients older than 65 years,
the excess non CV death was higher than the excess CV death.
Similar data were found in DOPPS III [19]. Our data might
underestimate CV mortality, since only prevalent patients were
included and there are data showing high rates of CV mortality in
the first year of dialysis [20–22]. However, mortality in the first
year of dialysis is greatly dependent on the characteristics of the
patients who are selected to start dialysis and pre-dialysis care they
have received [20].
Except for age, no large differences in baseline characteristics
were found between the patients dying from CVD, infection or
withdrawal. The higher prevalence of grafts in patients dying from
infections is in agreement with studies showing a higher incidence
of vascular access related infections in patients with synthetic grafts
as compared to native fistulas [23;24]. Furthermore, higher b2m
levels associated with infectious mortality were reported in the
HEMO study [25].
Withdrawal from dialysis was much more frequent than
anticipated. The death attributed to dialysis withdrawal varies
highly among studies. Among elderly patients in DOPPS the
proportion of death due to dialysis withdrawal varied between 1–
4% in Europe, to a maximum of 8% in North America and 14%
in Australia and New Zealand [19]. The proportion reported in
other studies from the US varied from 6 to 22% [26;27].and the
European ERA-EDTA reported a proportion of 5.2%, which
became 9.1% when the category ‘Suicide/refusal of treatment’
was added [7]. The 19% in Renine and the 20% in a French study
were in agreement with our study [28]. The large proportion of
patients dying from dialysis withdrawal was not limited to the
Dutch patients in our trial, suggesting that withdrawal is not only
an issue in a country where euthanasia has been legalized.
The varying percentage of patients dying after withdrawal of
dialysis treatment probably reflects differences in registration
practices. So far death due to dialysis withdrawal is poorly defined.
Dialysis withdrawal will not always be the cause of death when
dialysis is discontinued before death [29]. Notably, in case of
severe co-morbidity the co-morbid conditions rather than the
dialysis withdrawal itself may be the cause of death, especially
when patients die within 3 days after a decision to stop dialysis is
made [29].
In our study, deaths were adjudicated as ‘withdrawal from
dialysis’, if two or three out of three members of the adjudication
committee agreed on this. However, at the start of the study, no
clear cut criteria were given to define this aspect. Our findings with
respect to determinants of ‘death due to dialysis withdrawal’ were
similar to that reported by a study from the US identifying old age
and chronic diseases as risk factors for dialysis withdrawal [26].
Data from DOPPS III and the ERA-EDTA registry also showed
that the proportion of patients who stopped, increased with older
age [7;19]. Although patients who withdrew from dialysis had
much baseline co-morbidity in common, the factors associated to
withdrawal from dialysis were quite heterogeneous. CVD was
often one of the acute or chronic reasons to decide to stop HD
treatment. However, a broad scala of disease conditions was
present at the time of dialysis withdrawal. Until now little attention
has been paid to dialysis withdrawal in the nephrology commu-
nity. In the US written policies about appropriate initiation and
withdrawal from dialysis have been made [30]. Patients who refuse
dialysis, who are terminally ill or permanently unconscious are
patients for whom dialysis is inappropriate [30]. Before these
guidelines existed, fifteen percent of nephrologists reported in a
questionnaire to have written policies on dialysis withdrawal, after
Figure 1. The distribution of death causes across age groups at time of death.
doi:10.1371/journal.pone.0061155.g001
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these guidelines, still only a minority (30) of nephrologists reported
to have such a written policy [31].
Although the young dialysis patients still have a high CV risk,
the strong emphasis on the risk of CV death in dialysis patients
might be less justified in today’s European dialysis populations
[32]. Non CV causes of death and particularly withdrawal from
dialysis deserve more attention, particularly in the elderly.
In view of the importance of withdrawal from dialysis in daily
practice, well-defined criteria for the registration of dialysis
withdrawal are warranted. We would like to propose to define
death due to dialysis withdrawal as ‘death occurring more than 5
days after the last dialysis treatment which has been assigned as
such by patient and doctor’. A clear definition of dialysis
withdrawal is a needed to investigate the incidence and risk
factors for dialysis withdrawal. Mostly combinations of several co-
morbidities exist, such as CVD, infections, malnutrition, and low
quality of life. Regarding malnutrition, we previously showed that
nutritional status relates to quality of life [33], whereas reaching
clinical performance targets does not [34]. Possibly, less focus on
biochemical outcome targets for patients at high risk for dialysis
withdrawal, such as elderly dialysis patients might lead to a better
quality of life [35]. Potentially, less dietary restrictions and les
medication prescriptions might improve nutritional status. Poten-
tially treatable symptoms in hemodialysis, such as bone pain,
insomnia and emotional symptoms are undertreated, and if they
are treated, then mostly by primary care providers [36]. These
kinds of symptoms deserve more attention, since they are part of
patients’ quality of life.
Strengths of the present study are the availability of many
patient characteristics, which were collected in a standardized way
and second the adjudication process for causes of death by an
adjudication committee. However, a limitation in the adjudication
process was the lack of criteria to adjudicate deaths as ‘dialysis
withdrawal’, which might have led to an overestimation. Using our
proposed definition would probably lead to a lower percentage of
dialysis withdrawal, however we do not have data to make this
distinction retrospectively and therefore used the death causes as
adjudicated by the committee.
Another limitation is that we did not have individual patient
records from patients registered in Renine, therefore we were not
able to adjust for potential differences in age and sex distribution
between Renine and CONTRAST. Finally, the generalizability to
other populations may be considered as a limitation, since the
study population mainly consisted of Dutch patients.
In conclusion, although the absolute risk of death is much
higher, the proportion of CV deaths in a prevalent ESRD
population is similar to that of the general population. In older HD
patients CV and non-CV death risk are equally important.
Particularly the registration of dialysis withdrawal deserves
attention.
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